I 
110TH CONGRESS 
1ST SESSION H. R. 2241 
To amend the Public Health Service Act with respect to prevention and 
treatment of diabetes, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 9, 2007 
Mr. ENGEL (for himself, Mr. FOSSELLA, Mr. GENE GREEN of Texas, and Ms. 
DEGETTE) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act with respect to 
prevention and treatment of diabetes, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Diabetes Treatment 
and Prevention Act of 2007’’. 
SEC. 2. FINDINGS. 
Congress makes the following findings: 
(1) According to the Centers for Disease Con-
trol and Prevention, the prevalence of diabetes in the 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
United States has more than doubled in the past 
quarter-century. 
(2) The American Diabetes Association reports 
that there are now more than 20,000,000 people in 
the United States living with diabetes, with 
6,000,000 of these cases not yet diagnosed. Another 
54,000,000 people in the United States have ‘‘pre- 
diabetes’’, which means that they have higher than 
normal blood glucose levels, and are at increased 
risk of developing diabetes. 
(3) In 2002, the landmark Diabetes Prevention 
Program study found that lifestyle changes, such as 
diet and exercise, can prevent or delay the onset of 
type 2 diabetes, and that participants who made 
such lifestyle changes reduced their risk of getting 
type 2 diabetes by 58 percent. 
(4) The New York Times has reported that life-
style-based interventions to control diabetes have re-
sulted in positive outcomes for patients, yet despite 
these successes, such interventions were often 
unsustainable. While insurance companies cover the 
treatments of complications of unchecked diabetes, 
they tend not to cover the cheaper interventions to 
prevent such complications. 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
(5) According to the American Diabetes Asso-
ciation, in 2002, direct medical expenditures for dia-
betes 
totaled 
$91,800,000,000, 
including 
$23,200,000,000 
for 
diabetes 
care, 
and 
$24,600,000,000 for chronic complications attrib-
utable to diabetes. In that year, approximately 1 out 
of every 10 health care dollars was directed to diabe-
tes. 
(6) There is a need to increase the availability 
of effective community-based lifestyle programs for 
diabetes prevention and the ability of health care 
providers to refer patients for enrollment in such 
programs to prevent diabetes, reduce complications, 
and lower the costs associated with diabetes treat-
ment in the United States, and the Federal govern-
ment should encourage efforts to replicate the re-
sults of the Diabetes Prevention Program on a wider 
scale. 
SEC. 3. CENTERS FOR DISEASE CONTROL AND PREVEN-
TION DIVISION OF DIABETES TRANSLATION; 
DIABETES DEMONSTRATION PROJECTS. 
Title III of the Public Health Service Act (42 U.S.C. 
241 et seq.) is amended by inserting after section 317S 
the following: 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
‘‘SEC. 317T. CENTERS FOR DISEASE CONTROL AND PREVEN-
TION DIVISION OF DIABETES TRANSLATION. 
‘‘(a) IN GENERAL.—The Director of the Centers for 
Disease Control and Prevention shall establish within such 
Centers a Division of Diabetes Translation to eliminate 
the preventable burden of diabetes. 
‘‘(b) OFFICE.—The Division of Diabetes Translation 
shall carry out the following activities: 
‘‘(1) Supporting and carrying out diabetes sur-
veillance. 
‘‘(2) Conducting applied translational research, 
including research that will improve early detection, 
prevention, and access to quality care with respect to 
diabetes. 
‘‘(3) Working with States to establish and im-
prove diabetes control and prevention programs. 
‘‘(4) Coordinating the National Diabetes Edu-
cation Program in conjunction with the National In-
stitutes of Health. 
‘‘(5) Increasing education and awareness of dia-
betes. 
‘‘(6) Promoting greater awareness of the health 
effects of uncontrolled diabetes. 
‘‘(7) Other activities as deemed appropriate by 
the Director. 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
‘‘(c) APPROPRIATIONS.—There are authorized to be 
appropriated to carry out the activities of the Division of 
Diabetes Translation under this section $90,000,000 for 
fiscal year 2008, and such sums as may be necessary for 
each subsequent fiscal year. 
‘‘SEC. 317U. DEMONSTRATION PROJECTS FOR THE IDENTI-
FICATION AND TREATMENT FOR PERSONS DI-
AGNOSED WITH OR AT HIGH RISK FOR DIABE-
TES. 
‘‘(a) IDENTIFICATION
AND
PREVENTION
DEM-
ONSTRATION PROJECTS FOR PERSONS AT HIGH RISK FOR 
TYPE 2 DIABETES.— 
‘‘(1) IN GENERAL.— 
‘‘(A) DEVELOPMENT.—The Director of the 
Centers for Disease Control and Prevention (re-
ferred to in this section as the ‘Director’), in 
consultation with the Division of Diabetes 
Translation and academic centers, shall develop 
a set of pilot demonstration projects to evaluate 
various approaches to— 
‘‘(i) screening and identifying persons 
with pre-diabetes and undiagnosed diabe-
tes; and 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
‘‘(ii) providing identified persons with 
access to appropriate lifestyle interven-
tions. 
‘‘(B) LINKAGE TO DIABETES PREVENTION 
PROGRAM.—Such pilot projects shall be carried 
out with the goal of translating, using lifestyle 
interventions available in the community, the 
Diabetes Prevention Program clinical trial into 
interventions to reduce the incidence of type 2 
diabetes and its related complications in the 
United States population. 
‘‘(2) COOPERATIVE AGREEMENTS.— 
‘‘(A) IN
GENERAL.—The Director shall 
provide cooperative agreements and technical 
assistance to not more than 10 academic cen-
ters partnered with State or local public health 
departments to implement, monitor, and evalu-
ate such pilot projects. 
‘‘(B) APPLICATION.—Applicants shall sub-
mit to the Director an application, at such time, 
in such manner, and containing such informa-
tion as the Director may require, including— 
‘‘(i) information documenting the risk 
of the populations to be targeted by this 
intervention; and 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
‘‘(ii) information regarding the meth-
ods that shall be used to identify and 
screen these populations. 
‘‘(3) DURATION.—The cooperative agreements 
awarded under this subsection shall be awarded for 
a 2-year period, with the Director having the option 
to extend cooperative agreements for an additional 
2-year period. 
‘‘(4) EVALUATION.—Not later than 4 years 
after the date of the enactment of the Diabetes 
Treatment and Prevention Act of 2007, the Director 
shall submit to the Committee on Energy and Com-
merce of the House of Representatives and the Com-
mittee on Health, Education, Labor, and Pensions 
of the Senate a report evaluating the effectiveness of 
the program under this subsection and shall make 
such report publicly available. 
‘‘(5) AUTHORIZATION
OF
APPROPRIATIONS.— 
There 
are 
authorized 
to 
be 
appropriated 
$10,000,000 to carry out this subsection for each of 
fiscal years 2008 through 2012. 
‘‘(b) STATE PARTNERSHIPS FOR SURVEILLANCE AND 
EDUCATION.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
Control and Prevention, shall engage in partnerships 
with State and local health departments to carry out 
the following activities: 
‘‘(A) National, State, and local (to the de-
gree determined by the Secretary) surveillance 
of the following items: 
‘‘(i) The number of individuals and 
percentage of the population at risk for de-
veloping diabetes. 
‘‘(ii) The number of individuals and 
percentage of the population who have re-
ceived diabetes and high blood glucose 
screenings. 
‘‘(iii) Among those individuals who 
have been identified with pre-diabetes, the 
proportion that have been enrolled into 
lifestyle programs. 
‘‘(iv) The availability of interventions 
to prevent diabetes, and the access of the 
population to such interventions. 
‘‘(v) The number of individuals and 
percentage of population with both newly- 
diagnosed cases of diabetes and existing 
cases of diabetes, as well as the rates of in-
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
crease or decrease in newly-diagnosed dia-
betes. 
‘‘(vi) Other relevant factors as deter-
mined by the Secretary. 
‘‘(B) Education and information cam-
paigns to increase awareness among populations 
at high risk for diabetes, health care providers, 
and the general public, about the importance of 
primary prevention, ways to assess personal 
risk, and how to locate and access diabetes pre-
vention programs. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There 
are 
authorized 
to 
be 
appropriated 
$10,000,000 to carry out this subsection for each of 
the fiscal years 2008 through 2012. 
‘‘(c) TREATMENT DEMONSTRATION PROJECTS FOR 
CO-OCCURRING CHRONIC CONDITIONS.— 
‘‘(1) 
IN
GENERAL.—The 
Director, 
acting 
through the Division of Diabetes Translation, shall 
develop a pilot program to improve treatment for in-
dividuals with diabetes and other co-occurring chron-
ic conditions, such as mental illness, high blood pres-
sure, or cardiovascular disease, for which treatment 
may complicate the treatment for diabetes. 
‘‘(2) COOPERATIVE AGREEMENTS.— 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
‘‘(A) IN
GENERAL.—The Director shall 
provide cooperative agreements and technical 
assistance to not more than 10 academic cen-
ters, in partnership with State and local health 
departments, to implement, monitor, and evalu-
ate programs designed to improve health out-
comes in individuals with diabetes and other co- 
occurring chronic conditions. 
‘‘(B) APPLICATION.—Applicants shall sub-
mit to the Director an application, at such time, 
in such manner, and containing such informa-
tion as the Director may require, including in-
formation regarding the co-occurring conditions 
that shall be the subject of study. 
‘‘(C) PREFERENCE.—In awarding the co-
operative agreements under this subsection, the 
Director shall give preference for research that 
focuses on conditions which have a high preva-
lence among individuals with diabetes, or for 
which the treatment involved has the potential 
to impact adherence to diabetes treatment regi-
mens and that builds upon existing work de-
signed to improve the quality of care for pa-
tients with diabetes. 
VerDate Aug 31 2005 
21:27 May 10, 2007
Jkt 059200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS
‘‘(3) DURATION.—The cooperative agreements 
awarded under this subsection shall be awarded for 
a 2-year period, with the Director having the option 
to extend cooperative agreements for an additional 
2-year period. 
‘‘(4) EVALUATION.—Not later than 4 years 
after the date of the enactment of the Diabetes 
Treatment and Prevention Act of 2007, the Director 
shall submit to the Committee on Energy and Com-
merce of the House of Representatives and the Com-
mittee on Health, Education, Labor, and Pensions 
of the Senate a report evaluating the effectiveness of 
the program under this subsection in improving the 
health care outcomes for individuals with diabetes 
and other co-occurring chronic conditions and shall 
make such report publicly available. 
‘‘(5) APPROPRIATIONS.—There are authorized 
to be appropriated $10,000,000 to carry out this 
subsection for each of the fiscal years 2008 through 
2012.’’. 
Æ 
VerDate Aug 31 2005 
22:46 May 12, 2007
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6301
E:\BILLS\H2241.IH
H2241
pwalker on PROD1PC71 with BILLS